Nyrada Inc (ASX:NYR) 57% Reduction in Total Cholesterol from Nyrada's NYX-PCSK9i In Vivo Study
Nyrada Inc (ASX:NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholesterolemia (high cholesterol).